| Project leader |
Project title |
| Battegay |
Cost-effectiveness of genotypic and phenotypic antiretroviral resistance testing in HIV infected patients |
| Ebnöther |
MO1-305: A Phase IV Long-Term Safety Surveillance Study of Subjects Enrolled in the M98-863 Study |
| Fehr |
A Phase IIb, multicentre, randomised, double-blind, active-controlled trial comparing neuropsychiatric adverse event profile of etravirine 400mg q.d. vs. efavirenz 600mg q.d. in combination with 2 nucleos/tide reverse transcriptase inhibitors in antiretroviral therapy-naive HIV-1 infected subjects (SENSE-study) |
|
Ready to start? Assessing and supporting HIV-infected individual's readiness to start antiretroviral therapy |
|
SENSE-study: Neuropsychiatric adverse event profile of etravirine versus stocrin in HIV-1 infected subjects |
| Fischer |
Determination of the distribution and topology of cell-Associated HIV-RNA in blood and lymphoid tissue of HIV-infected patients on effective combination antiretroviral therapy |
|
Determination of the viral transcriptional activity and productivity of HIV-infected peripheral blood mononuclear cells and macrophages at the single cell level in vivo. |
|
Characterization of extrahepatic Hepatitis C Virus Replication in vivo |
|
Maintenance and induction of latent infection of HIV-1 by innate cellular defense mechanisms in vivo |
|
In vivo Correlates of HIV-1 Latency During Antiretroviral Therapy; Individualized Approaches to Quantify Highly Variable Viral Nucleic Acids |
| Flepp |
INITIO: An open randomised trial to evaluate different therapeutic strategies of combination therapy for HIV-1 infection |
|
AI424-034: A Phase III - study comparing the antiviral efficacy and safety of BMS-232632 with Efavirenz; each in combination with fixed dose Zidovudine-Lamivudine |
|
AI424-008: Evaluation of the Safety and Antiviral Efficacy of a Novel HIV-1 Protease Inhibitor, BMS-232632, in Combination with D4T and 3TC as Compared to a Reference Combination Regimen |
|
M98-863: A Randomized, Double-Blind, Phase III Study of ABT-378/Ritonavir Plus Stavudine and Lamivudine vs. Nelfinavir Plus Stavudine and Lamivudine in Antiretroviral-Naive HIV-Infected Subjects
|
|
THE ZURICH PROMETHEUS STUDY: ddI QD / d4T / Nelfinavir in HIV-Infected Drug Users Enrolled in Opiate Substitution Programs
|
| Gaab Weber |
SWISSIT Study: Randomized controlled trial of stress management training in patiens with HIV infection |
| Hasse |
Determinants of unprotected sex among HIV-infected persons. The Swiss HIV Cohort Study |
|
Clinical problems in ageing HIV-patients: Experiences from the Swiss HIV Cohort Study
|
|
Extended-Spectrum β-Lactamase-producing gram-negative pathogens in community-acquired urinary tract infections: An increasing challenge for antimicrobial therapy
|
| Hersberger |
Is there an association of the inducible nitric oxide synthase polymorphism with HIV replication and pathogenesis?
|
| Hirschel |
STACCATO: A Randomized Trial of CD4 guided Treatment Interruption, Compared to Continuous Treatment, for HIV Infection. |
|
Swiss Intermittent Therapy Trial - 2 (SITT): Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) plus treatment interruptions for stimulating the anti-HIV immune response. |
|
A Trial of Intermittent Therapy for HIV Infection (Swiss-Spanish Intermittent Therapy Trial - SSITT) |
| Huber Weber |
Self-reported injection and non-injection drug use in HIV-infected persons in the SHCS, and influence of drug use behaviour on the uptake of, adherence to, and outcome of antiretroviral therapy and outcome of HIV infection |
| Karrer |
Immunologic response of patients treated with combination antiretroviral therapy containing tenofovir and/or didanosine. |
|
INTENSE-study: A Phase IIIb / IV randomized, controlled study evaluating an intensification treatment strategy of adding Enfuvirtide (ENF) to an oral highly active antiretroviral therapy (HAART) in treatment experienced patients. |
|
Therapy-induced functional and phenotypic alterations in HIV-specific cellular immunity (Tiffany-study) |
|
Influence of persistent viral infections on immune senescence |
|
Antigen specificity of activated T cells in patients with untreated HIV-1 infection. |
| Kovari |
Association of Noncirrhotic Portal Hypertension (NCPH) in HIV-infected Persons and Antiretroviral Therapy with Didanosine (DDI)
A nested case control study
|
|
Prolonged Antiretroviral Therapy (ART) and Risk for Chronic Elevation of Alanine Aminotransferase (ALT) in HIV-infected Persons without Hepatitis B or C Virus Co-infections |
|
Liver-related mortality in HIV-infected patients without HBV and HCV infection in the D:A:D study. |
|
Liver-related mortality in HIV-infected patients without HBV and HCV infection: The Data Collection on Adverse Events of Anti-HIV Drugs Study |
|
Prävalenz und Entwicklung antimikrobieller Resistenzen bei E. coli im Urin im Raum Zürich als Grundlage für neue Richtlinien zur antibiotischen Therapie der unkomplizierten Zystitis |
| Kündig |
Therapeutic vaccination against chronic Hepatitis B by intralymphatic administration of a naked DNA vaccine. |
| Ledergerber |
EuroSIDA 2006-2010: Clinical and virological outcome of patients with HIV under care in Europe |
|
Immigrants in the Swiss HIV Cohort Study: Characteristics, time-trends and retention rates |
|
The effect of HIV clade on Immunologic and clinical HIV progression in antiretroviral naïve patients; A Canadian/Swiss Colaborative Study |
| Mühlemann |
Antibiotic utilization in Swiss hospitals; as part of project 'Sentinel surveillance of antibiotic resistance in Switzerland. |
| Müller |
Evolution of virulence in the Swiss HIV Cohort Study |
| Mueller |
SMART (A large Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy) |
|
HIV and solid organ transplantation: Summary of the Swiss experience |
|
Significance of the specific cellular response against Human Herpes virus 8 in control of Kaposi’s sarcoma in HIV-infection |
| Mueller Bischoff |
Prevalence and predictors of low vitamin D levels in the Swiss HIV Cohort Study |
| Mueller Buhler |
Islet xenotransplantation in the pig-to-nonhuman primate model: Evaluation of new immunosuppressive strategies and cross-species infections |
| Opravil |
Simplified maintenance therapy (SMT) in HIV infection |
|
Hoffmann-La Roche Protocol NR15961: A Randomized, Open-Label, Multicenter, Phase III, Three Arm Study Evaluating the Efficacy and Safety of Pegylated-Interferon alfa-2a (Ro 25-8310) Monotherapy versus Combination Therapy of Pegylated-Interferon alfa 2a with Ribavirin (Ro- 20-9963) versus Combination Therapy of Interferon alfa-2a (Ro 22-8181) with Ribavirin for 48 Weeks and 24 Weeks of Follow-up in Patients with Chronic Hepatitis C Co-infected with Human Immunodeficiency Virus |
|
Prospective study of switch to 3TC monotherapy with evaluation of replication capacity in patients with virologic failure and 3TC resistance |
|
Prospective evaluation of non-invasive fibrosis assessment and breath test for quantification of liver function in patients with HIV/HCV-coinfection. |
|
Treatment initiation with zidovudine-containing potent ART impairs the CD4 cell recovery but not the clinical efficacy. |
|
A Long Term Safety and Efficacy Study of Viracept in Combination with 2 Nucleoside Reverse Transcriptase Inhibitors as Initial Treatment in HIV-infected Patients (Protocol AG1343-1260). |
|
Tipranavir clinical studies |
|
Fosamprenavir: A phase III, randomized, multicenter, parallel group, open-label, three arm study to compare the efficacy and safety of two dosing regimens of GW433908/ritonavir (700 mg/100 mg twice daily or 1400 mg/200 mg once daily) versus lopinavir/ritonavir (400 mg/100 mg twice daily) for 48 weeks in protease inhibitor experienced HIV-infected adults experiencing virological failure (Protocol APV30003) |
|
Vicriviroc (SCH417690, experimental CCR5 antagonist): Safety and Efficacy of Vicriviroc in HIV-Infected Treatment-Naïve and Treatment-Experienced Subjects |
|
Clinical Benefit of Early Initiation of Antiretroviral Therapy in Patients with Asymptomatic HIV Infection: A Nested Study of Two Matched Cohorts within the Swiss HIV Cohort Study.
|
|
KLEAN Study: A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 (Fosamprenavir, 700mg BID) plus ritonavir (100mg BID) Versus Lopinavir/ritonavir (400mg/100mg BID) when Administered in Combination with the Abacavir/Lamivudine (600mg/300mg) Fixed-Dose Combination Tablet QD in Antiretroviral-Naïve HIV-1 Infected Adults Over 48 Weeks |
|
TMC125 (Etravirine, experimental NNRTI) Phase II-III studies in patients with drug-resistant HIV infection. |
|
Pulmonary hypertension related to HIV-infection: epidemiological, pathophysiological and therapeutical studies |
|
TMC114 (Darunavir, HIV protease inhibitor): Several phase II - III multicenter studies examining the efficacy and tolerability of this new protease inhibitor both in treatment-experienced and treatment-naive HIV-1 infected subjects. |
|
Raltegravir (HIV integrase inhibitor): Two phase II and III multicenter studies examining the efficacy and tolerability of this new integrase inhibitor in treatment-experienced HIV-1 infected subjects with multiple drug resistance. |
|
Maraviroc (UK-427,857, experimental CCR5 antagonist): Three phase II - III multicenter studies examining the efficacy and tolerability of this new entry inhibitor both in treatment-experienced and treatment-naive HIV-1 infected subjects. |
| Oxenius |
Ex vivo analysis of productive HIV-1 infection in antigen-specific CD4+ T-cells |
| Ruef |
Assessment of antibiotic use and antibiotic resistance in long term care facilities and its impact on antimicrobial resistance in acute care hospitals |
|
Antibiotic utilization in Swiss hospitals |
|
Evaluation of Antifungal Therapy at a Large European University Hospital |
|
Double-blind, randomized phase III study to assess safety and efficacy of isavuconazole in comparison with caspofungin followed by voriconazole in the treatment of candidemia and other invasive candida infections |
|
Double blind, randomized, phase III study to assess the safety and efficacy of isavuconazole compared with voriconazole for the treatment of invasive fungal infections caused by Aspergillus species and other filamentous fungi |
|
Risk factors for persistance of MRSA colonization: impact of decolonization measures |
|
Outcome of enterococcal bacteremia in patients at a tertiary care university hospital |
|
Impact of infection control interventions on the incidence of sternal wound infections in open heart surgery |
|
Impact of teaching interventions on the incidence of catheter-related bacteremia in intensive care units |
| Speck |
Impact of triggering Toll-like receptor 7/8 on HIV replication: in vitro and in vivo studies |
|
CD4 Expression level on HIV target cells: A prognostic factor for disease progression |
|
CD4 epxression level on HIV target cells: a prognostic factor for disease progression |
|
Examining the impact of IFN-alpha and IL-7 on Hepatitic C: a phase I clinical trial and in vivo mouse model |
|
Role of negative feedback mechanism(s) in HIV pathogenesis |
|
CD4 expression level on HIV target cells: A prognostic factor for disease progression? |
|
Epstein-Barr Virus entry into epithelial cells |
|
Impact of HIV-induced gene products on HIV replication |
|
Do HIV+patients with lymphoma respond differently to TLR9 tirggering than matched HIV+ patients with no lymphoma. |
|
Is triggering Toll-like receptor (TLR) 9 involved in the pathogenesis of HIV associated brain lymphoma? |
|
CD4+ expression level on HIV target cells: a prognostic factor for disease progression? |
|
Evaluation of a mouse model for the study of HIV |
|
Investigation of toll-like receptor triggering on HIV-replication |
|
Are polymorphisms of the toll-like receptor 9 gene associated with HIV replication and pathogenesis? |
|
Einfluss von Zytokinen auf HIV in menschlichem lymphozytärem Gewebe, infiziert ex vivo. |
|
Exploitation of signaling through the cellular receptor complex by HIV-1 to facilitate own replication. |
|
Exploitation of signaling through the cellular receptor complex by HIV-1 to facilitate own replication. |
| Speck Nadal |
Do HIV+ patients with lymphoma respond differently to Toll-like receptor (TLR) 9 triggering than matched HIV+ patients with no lymphoma? |
|
Is triggering Toll-like receptor 9 involved in the pathogenesis of HIV-associated brain lymphoma? |
| Speck Oxenius |
Cross-sectional analysis of the HIV-specific CD8 immune response in defined groups of HIV-infected patients: correlation with the clinical course and host genetic factors. |
| Trkola Günthard |
Structured treatment interruption combined with passive immunization in HIV infected patients: A phase II trial |
| Vernazza |
Immunomodulatory effects of atorvastatin in treatment interruption as a model for primary HIV infection: Atorvastatin in treatment interruption. |
|
Immunomodulatory effects of atorvastatin in treatment interruption as a model for primary HIV infection: Atorvastatin in treatment interruption. |
| Vernazza Günthard |
Monotherapy in Switzerland (MOST-Study) |
| Weber |
QUEST Study: Evaluation of two therapeutic HIV vaccination regimens in HAART-treated primary HIV infection subjects following analytical treatment interruption: a randomised, placebo-controlled study. |
|
Diarrhea in HIV-infected persons |
|
Hepatitis B Virus Co-Infection in the Swiss HIV Cohort Study: Influence of HBV genotype, Hepatitis C Virus Co-infection and Antiretroviral Treatment on Clinical Outcome and HBV Clearance |
|
Is HCV infection a risk factor for Diabetes mellitus type 2 and consequently a risk factor for cardiovascular disease among HIV infected persons?
|
|
ENDOPACT Study: Effect of Atazanavir on Endothelial Function in HIV-Infected Patients Compared to Standard Proteinase Inhibitors on top of Potent Antiviral Combination Therapy |
|
Antiretroviral therapy of HIV-infected intravenous drug users and persons in a drug addiction treatment program: The Swiss HIV Cohort Study |
|
Treatment of Hepatitis C Infection in HIV and HCV Co-infected Persons in the Swiss HIV Cohort Study: Observational Analysis of Epidemiology of Treatment, Treatment Course and Outcome
|
|
ARTEN: Open-label, randomised clinical trial to compare the virological efficacy and safety of Atazanavir/Ritonavir on a background of Tenofovir and Emtricitabine vs. Nevirapine on same background, in HIV-1-infected patients who have received no previous antiretroviral treatment. |
|
CNA109586 – Study of Once-Daily Abacavir/Lamivudine versus Tenofovir/Emtricitabine, Administered with Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects |
|
Risk-Factors for and Outcome of Hyperlactatemia in HIV-infected Persons: Is there a Need for Routine Lactate Monitoring?
|
| Zinkernagel |
AI424-044: A Study to Assess Long-Term Antiviral Activity, Safety, Including Serum Lipids, and Tolerability of BMS-232632 in Combination with Stavudine (d4T) and Lamivudine (3TC) in Subjects Previously Treated with Nelfinavir or BMS-232632 |
